Durable activity of NVL-655 and zidesamtinib in heavily pre-treated patient populations supports ongoing Phase 2 investigation in earlier lines of treatment "Our development strategy has been anchored ...

Zidesamtinib is a novel brain-penetrant ROS1-selective inhibitor created with the aim to overcome limitations observed with currently available ROS1 inhibitors. Zidesamtinib is designed to remain ...

RESEARCH TRIANGLE PARK, N.C., April 27, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the European Medicines Agency (EMA) has granted access to the Priority ...

The case study, which showed prolonged disease control achieved with gilteritinib in a previously-treated patient with AML with an inv(2)(p23q13) translocation, indicates that gilteritinib can also be ...

The ALK inhibitors market is projected to expand in the near future. This growth is driven by the rising number of cancer diagnoses, heightened awareness of ALK inhibitors, and the increasing number ...

Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer Adult-onset neuroblastoma ...

Alectinib, a potent anaplastic lymphoma kinase (ALK) inhibitor, significantly improved disease-free survival (DFS) at 2 years compared with chemotherapy in patients with completely resected ALK+ ...

Researchers at Boston Children's Hospital and Harvard Medical School have explored the possibility of using anaplastic lymphoma kinase (ALK) as a target for the application of ALK.CAR T cells to treat ...

Drugs targeting mutations in the anaplastic lymphoma kinase gene (ALK) are already useful in lung cancer, but they may also find a use in the treatment of leukemias. ALK mutations were found in two ...